🩸Facts about Myelofibrosis:

Transplantation & Curative Intent

#Myelofibrosis #MF #Hematology #StemCellTransplant #AlloHSCT #BoneMarrowTransplant #BloodDisorders #JAK2 #CALR #MPL #TransplantMedicine #RIC #MedEd #HEMEHUB

This study identifies PD-1+CD8+ TSCM-like regulatory cells in G-CSF–mobilized donors that balance #GVHD suppression and #GraftVersusLeukemia preservation after #alloHSCT, revealing a potential #biomarker for optimal donor selection.

#OpenAccess #STTT: doi.org/10.1038/s413...

A donor PD-1+CD8+ TSCM-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - A donor PD-1+CD8+ TSCM-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease

Scientists identified a donor-derived PD-1⁺CD8⁺ TSCM-like regulatory subset that alleviates #aGvHD, preserves GVL, supports immune reconstitution, offering #biomarkers for donor selection & potential cell therapy in #alloHSCT.

#STTT #OpenAccess: doi.org/10.1038/s413...

#Modulen-IBD for the prevention of #malnutrition and maybe #GVHD in #alloHSCT and promising effects on #microbiota
Ready to start recruitment for the multicenter #RCT (NCT07010068).
authors.elsevier.com/a/1lNYT8Yy15...
@sghmd.bsky.social

📄 [EHA2025] – MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress.

👉 Read the press release: www.maatpharma.com/may-14-2025-...

#EHA #EAP #Phase3 #aGvHD #alloHSCT #Microbiome #Oncology #Cancer #Hematology

Orca Bio’s T-cell therapy shows promise in haematological malignancies - PharmaTimes The company is preparing to submit the results to the FDA this year

#OrcaBio #allogeneiccelltherapy #OrcaT #Tcelltherapy #investigationalallogeneicTcellimmunotherapy #PrecisionTtrial #acutemyeloidleukaemia #acutelymphoblasticleukaemia #highriskmyelodysplasticsyndrome #mixedphenotypeacuteleukaemia #alloHSCT #cGvHD #alloHSCT
pharmatimes.com/news/orca-bi...

‘Breakthrough’ Leukemia Drug Also Portends ‘Quantum Leap’ In Cost - KFF Health News A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.

Interesting that nobody writes about cost of #alloHSCT

‘Breakthrough’ Leukemia Drug Portends ‘Quantum Leap’ In Cost http://khn.org/NzYxNDgw